1
|
Giménez-Richarte Á, de Salazar MO, Arbona C, Giménez-Richarte MP, Collado M, Fernández PL, Quiles F, Clavijo C, Marco P, Ramos-Rincon JM. Prevalence of Chikungunya, Dengue and Zika viruses in blood donors: a systematic literature review and meta-analysis. BLOOD TRANSFUSION = TRASFUSIONE DEL SANGUE 2022; 20:267-280. [PMID: 34694219 PMCID: PMC9256504 DOI: 10.2450/2021.0106-21] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Accepted: 07/20/2021] [Indexed: 11/07/2022]
Abstract
BACKGROUND Blood transfusion centres should understand the epidemiology of emerging diseases that are transmissible through the transfusion of blood components. The risk of transmission of arboviruses through this route has become apparent in recent years. The aim of our study is to summarise the reported prevalence (viraemic rate, seroprevalence and/or antigen detection) of Chikungunya (CHIKV), Dengue (DENV) and Zika (ZIKV) viruses in blood donors according to screening test used and world region. MATERIALS AND METHODS We conducted a systematic literature review and meta-analysis having searched for information in the main bibliographic databases (MEDLINE, Embase, and Scopus). The prevalence for each of the viruses was calculated according to the screening test used and geographic location. RESULTS We included 18 records on CHIKV, 71 on DENV, and 27 on ZIKV. The highest prevalences of RNA for CHIKV were 1.9% in Puerto Rico (2014), 1.0% in Thailand (2009), and 1.0% in French Polynesia (2014-15). The highest prevalences of RNA for DENV were 5.5% in Saudi Arabia (2015-16), 2.3% in Madeira, Portugal (2012-13), and 0.6% in Brazil (2012). The highest prevalences of RNA for ZIKV were 2.8% in French Polynesia (2013-14), 2.7% in Brazil (2015-16), and 1.8% in Martinique (2016). Overall seroprevalence, as assessed by IgG antibodies, was 21.6% for CHIKV, 24.0% for DENV, and 5.1% for ZIKV. DISCUSSION Our study shows a high proportion of donors who are viraemic and asymptomatic, especially during outbreaks, with prevalences surpassing 5% for DENV, 1% for CHIKV, and 2% for ZIKV. These data confirm a clear threat to blood transfusion safety. The elevated seroprevalence for these three arboviruses is also indicative of their wide circulation in populations, correlating with an increased risk of infected but asymptomatic donors. Health centres and institutions must address this threat, especially in tropical regions where the biggest outbreaks occur.
Collapse
Affiliation(s)
| | | | - Cristina Arbona
- Valencian Community Blood Transfusion Centre, Valencian Community, Spain
| | | | - Miriam Collado
- Valencian Community Blood Transfusion Centre, Valencian Community, Spain
| | - Pedro L Fernández
- Valencian Community Blood Transfusion Centre, Valencian Community, Spain
| | - Francisco Quiles
- Valencian Community Blood Transfusion Centre, Valencian Community, Spain
| | - Carlos Clavijo
- Valencian Community Blood Transfusion Centre, Valencian Community, Spain
| | - Pascual Marco
- Service of Haematology, General University Hospital of Alicante-ISABIAL, Alicante, Spain
- Clinical Medicine Department, Miguel Hernandez University of Elche, Alicante, Spain
| | | |
Collapse
|
2
|
Borena W, Kimpel J, Gierer M, Rössler A, Riepler L, Oehler S, von Laer D, Miholits M. Characterization of Immune Responses to SARS-CoV-2 and Other Human Pathogenic Coronaviruses Using a Multiplex Bead-Based Immunoassay. Vaccines (Basel) 2021; 9:611. [PMID: 34200301 PMCID: PMC8229387 DOI: 10.3390/vaccines9060611] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2021] [Revised: 05/31/2021] [Accepted: 06/02/2021] [Indexed: 11/17/2022] Open
Abstract
Serological assays that simultaneously detect antibodies to multiple targets of SARS-CoV-2 and to other structurally related coronaviruses provide a holistic picture of antibody response patterns. Well-validated multiplex immunoassays are scarce. Here, we evaluated the performance of an 11-plex serological assay capable of detecting antibodies directed to four antigenic targets of SARS-CoV-2 and to S1 proteins of other human pathogenic coronaviruses. We used 620 well-characterized sera (n = 458 seropositive and n = 110 seronegative for SARS-CoV-2 in the pre-SARS-CoV-2 era and n = 52 seronegative for SARS-CoV-2 in the era of SARS-CoV-2) as positive and negative standards. We calculated the sensitivity, specificity, as well as positive and negative predictive values, including a 95% confidence interval. The difference in mean fluorescence intensity (95% CI) was used to assess a potential cross-reaction between antibodies to SARS-CoV-2 and the other coronaviruses. The sensitivity (95% CI) of detecting anti-SARS-CoV-2 antibodies to four antigenic targets ranged from 83.4% (76.7-86.7) to 93.7% (91.0-95.7) and the specificity from 98.2% (93.6-99.8) to 100% (96.7-100). We observed no obvious cross-reaction between anti-SARS-CoV-2 antibodies and antibodies to the other coronaviruses except for SARS-CoV-1. The high sensitivity and specificity warrant a reliable utilization of the assay in population-based seroprevalence surveys or vaccine efficacy studies.
Collapse
Affiliation(s)
- Wegene Borena
- Institute of Virology, Department of Hygiene, Microbiology and Public Health, Medical University of Innsbruck, 6020 Innsbruck, Austria; (J.K.); (A.R.); (L.R.); (D.v.L.)
| | - Janine Kimpel
- Institute of Virology, Department of Hygiene, Microbiology and Public Health, Medical University of Innsbruck, 6020 Innsbruck, Austria; (J.K.); (A.R.); (L.R.); (D.v.L.)
| | - Melanie Gierer
- Thermo Fisher Scientific, Bender MedSystems GmbH, Campus Vienna Biocenter 2, 1030 Vienna, Austria; (M.G.); (S.O.); (M.M.)
| | - Annika Rössler
- Institute of Virology, Department of Hygiene, Microbiology and Public Health, Medical University of Innsbruck, 6020 Innsbruck, Austria; (J.K.); (A.R.); (L.R.); (D.v.L.)
| | - Lydia Riepler
- Institute of Virology, Department of Hygiene, Microbiology and Public Health, Medical University of Innsbruck, 6020 Innsbruck, Austria; (J.K.); (A.R.); (L.R.); (D.v.L.)
| | - Susanne Oehler
- Thermo Fisher Scientific, Bender MedSystems GmbH, Campus Vienna Biocenter 2, 1030 Vienna, Austria; (M.G.); (S.O.); (M.M.)
| | - Dorothee von Laer
- Institute of Virology, Department of Hygiene, Microbiology and Public Health, Medical University of Innsbruck, 6020 Innsbruck, Austria; (J.K.); (A.R.); (L.R.); (D.v.L.)
| | - Markus Miholits
- Thermo Fisher Scientific, Bender MedSystems GmbH, Campus Vienna Biocenter 2, 1030 Vienna, Austria; (M.G.); (S.O.); (M.M.)
| |
Collapse
|
3
|
Performance of Zika Assays in the Context of Toxoplasma gondii, Parvovirus B19, Rubella Virus, and Cytomegalovirus (TORCH) Diagnostic Assays. Clin Microbiol Rev 2019; 33:33/1/e00130-18. [PMID: 31826871 DOI: 10.1128/cmr.00130-18] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Infections during pregnancy that may cause congenital abnormalities have been recognized for decades, but their diagnosis is challenging. This was again illustrated with the emergence of Zika virus (ZIKV), highlighting the inherent difficulties in estimating the extent of pre- and postnatal ZIKV complications because of the difficulties in establishing definitive diagnoses. We reviewed the epidemiology, infection kinetics, and diagnostic methods used for Toxoplasma gondii, parvovirus B19, rubella virus, and cytomegalovirus (TORCH) infections and compared the results with current knowledge of ZIKV diagnostic assays to provide a basis for the inclusion of ZIKV in the TORCH complex evaluations. Similarities between TORCH pathogens and ZIKV support inclusion of ZIKV as an emerging TORCH infection. Our review evaluates the diagnostic performance of various TORCH diagnostic assays for maternal screening, fetal screening, and neonatal screening. We show that the sensitivity, specificity, and positive and negative predictive value of TORCH complex pathogens are widely variable, stressing the importance of confirmatory testing and the need for novel techniques for earlier and accurate diagnosis of maternal and congenital infections. In this context it is also important to acknowledge different needs and access to care for different geographic and resource settings.
Collapse
|
4
|
Liu R, Wang X, Ma Y, Wu J, Mao C, Yuan L, Lu J. Prevalence of Zika virus in blood donations: a systematic review and meta-analysis. BMC Infect Dis 2019; 19:590. [PMID: 31277583 PMCID: PMC6612077 DOI: 10.1186/s12879-019-4226-6] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2018] [Accepted: 06/26/2019] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND Transfusion-Transmitted Zika virus (TT-ZIKV) has become an emerging threat to world blood banks due to the fast spread of ZIKV epidemics and high rate of asymptomatic infections. For the risk assessment of ZIKV infection in blood products, relevant studies in blood donations or blood donors tested for ZIKV were collected and analyzed systematically. The overall prevalence of ZIKV infection were estimated through meta-analysis and potential risk factors were detected. The results will provide important clues for the protocol design of blood screening tests. METHODS Relevant articles about the rate of ZIKV detected in blood samples were identified from PubMed, Scopus and Web Of Science using key terms search strategy until October 7, 2017. Eligible articles were screened following inclusion and exclusion criteria. Meta-analysis and subgroup analyses were performed by software R3.4.1. Overall postdonation and posttransfusion follow-ups were analyzed. RESULTS Ten literatures (528,947 blood samples) were included for meta-analysis. The overall pooled prevalence of ZIKV (RNA and antibody) in blood donations was 1.02% (95%CI 0.36-1.99). The pooled prevalence of ZIKV RNA in blood donations was 0.85% (95%CI 0.21-1.88) less than the pooled prevalence of anti-ZIKV antibodies 1.61% (95%CI 0.03-5.21), however the difference was not statistically significant (p = 0.52). The prevalence varied significantly in different geographical regions (p < 0.001). Blood donations were more than two times likely to be infected by ZIKV in Zika epidemic period (1.37, 95%CI 0.91-1.91) than in non-epidemic period (0.61, 95%CI 0-2.55). The prevalence of anti-ZIKV antibodies (1.61, 95%CI 0.03-5.21) was almost twice as much as ZIKV nucleic acid detected in blood donations (0.85, 95%CI 0.21-1.88). However, statistically significant differences were not observed. A total of 122 ZIKV positive blood donors were followed, of which 48 (39%) reported symptoms postdonation, but none of the 13 followed recipients reported any clinical symptoms related to Zika infection posttransfusion. CONCLUSION The pooled prevalence of Zika infection in blood donations was 1.02%. The prevalence varied greatly and reached to high-risk level in most of the situations. The results suggest that nucleic acid tests (NAT) for blood screening and pathogen reduction/inactivation technology (PRT) should be implemented in Zika-endemic areas and appropriate strategies should be designed according to different conditions. More studies are needed in the future to provide more evidence.
Collapse
Affiliation(s)
- Rongfei Liu
- School of Public Health, Sun Yat-sen University, 74 Zhongshan Road 2, Guangzhou, 510080, Guangdong Province, China.,Foshan Women and Children Hospital Affiliated to Southern Medical University, Foshan, Guangdong Province, China
| | - Xuanzhuo Wang
- School of Public Health, Sun Yat-sen University, 74 Zhongshan Road 2, Guangzhou, 510080, Guangdong Province, China.,One Health Center of Excellence for Research &Training, Sun Yat-sen University, Guangzhou, China
| | - Yu Ma
- Guangzhou Center for Disease Control and Prevention, Guangzhou, Guangdong Province, China
| | - Jianyong Wu
- School of Public Health, Sun Yat-sen University, 74 Zhongshan Road 2, Guangzhou, 510080, Guangdong Province, China.,One Health Center of Excellence for Research &Training, Sun Yat-sen University, Guangzhou, China
| | - Chen Mao
- Department of Epidemiology, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, China
| | - Lihong Yuan
- School of Public Health, Sun Yat-sen University, 74 Zhongshan Road 2, Guangzhou, 510080, Guangdong Province, China. .,One Health Center of Excellence for Research &Training, Sun Yat-sen University, Guangzhou, China.
| | - Jiahai Lu
- School of Public Health, Sun Yat-sen University, 74 Zhongshan Road 2, Guangzhou, 510080, Guangdong Province, China. .,One Health Center of Excellence for Research &Training, Sun Yat-sen University, Guangzhou, China. .,Key Laboratory of Tropical Disease Control of Ministry of Education, Sun Yat-sen University, Guangzhou, China. .,State Key Laboratory of Vector-borne Infectious Disease (Hainan), Haikou, Hainan Province, China.
| |
Collapse
|
5
|
Warnecke JM, Lattwein E, Saschenbrecker S, Stöcker W, Schlumberger W, Steinhagen K. Added value of IgA antibodies against Zika virus non-structural protein 1 in the diagnosis of acute Zika virus infections. J Virol Methods 2019; 267:8-15. [DOI: 10.1016/j.jviromet.2019.02.005] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2018] [Revised: 02/14/2019] [Accepted: 02/15/2019] [Indexed: 12/16/2022]
|
6
|
Zamarina TV, Khrapova NP, Pimenova EV, Khanani EI, Viktorov DV, Toporkov AV. [Zika fever immunodiagnostics: overview of test systems.]. Vopr Virusol 2019; 64:150-155. [PMID: 32163680 DOI: 10.36233/0507-4088-2019-64-4-150-155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2019] [Accepted: 06/11/2019] [Indexed: 11/05/2022]
Abstract
The threat of rapid spread of Zika virus beyond endemic regions has given rise to more research in field of epidemiology and clinic, as well as to the search for Zika fiver new diagnostic and preventive tools. Between 2013 and 2017 in Russia 18 cases of infection transmission by travellers were reported. Fever Zika reference monitoring center in Volgograd Research AntiPlague Institute (Volgograd, Russian Federation) provides counseling and methodological assistance on laboratory diagnosis and monitoring of Zika fever. In this regard, a literature review of commercial test systems for immunodiagnostics of this infection was performed. Currently, a number of test systems for solid-phase enzyme-linked immunoassay method (ELISA), immunochromatography and indirect immunofluorescent method (IIFT) have been developed for immunodiagnostics of Zika fever. Euroimmun Ltd. remains the only manufacturer that has access to detailed information on validation of the specificity of the produced diagnostic kits. Independent studies confirm that Euroimmun test systems have high specificity and high sensitivity, which is proved by the study of the material from various populations, including Europeans travelling to Zika virus endemic regions and people residing in these regions. A detailed overview of characteristics of Euroimmun test systems for immunodiagnostics of Zika fever allows us to conclude that there is a rationale for the use of these test systems for Russian Federation sanitary protection by identification of antibodies in patients, presumably infected with the Zika virus.
Collapse
Affiliation(s)
- T V Zamarina
- Volgograd Research Anti-Plague Institute, Volgograd, 400131, Russian Federation
| | - N P Khrapova
- Volgograd Research Anti-Plague Institute, Volgograd, 400131, Russian Federation
| | - E V Pimenova
- Volgograd Research Anti-Plague Institute, Volgograd, 400131, Russian Federation
| | - E I Khanani
- Volgograd Research Anti-Plague Institute, Volgograd, 400131, Russian Federation
| | - D V Viktorov
- Volgograd Research Anti-Plague Institute, Volgograd, 400131, Russian Federation
| | - A V Toporkov
- Volgograd Research Anti-Plague Institute, Volgograd, 400131, Russian Federation
| |
Collapse
|
7
|
Badolo A, Burt F, Daniel S, Fearns R, Gudo ES, Kielian M, Lescar J, Shi Y, von Brunn A, Weiss SR, Hilgenfeld R. Third Tofo Advanced Study Week on Emerging and Re-emerging Viruses, 2018. Antiviral Res 2018; 162:142-150. [PMID: 30597184 PMCID: PMC7132404 DOI: 10.1016/j.antiviral.2018.12.015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2018] [Accepted: 12/24/2018] [Indexed: 11/23/2022]
Abstract
The Third Tofo Advanced Study Week on Emerging and Re-Emerging Viruses (3rd TASW) was held in Praia do Tofo, Mozambique, from September 02 to 06, 2018. It brought together 55 participants from 10 African countries as well as from Belgium, China, Germany, Singapore, and the USA. Meeting sessions covered aspects of the epidemiology, diagnosis, molecular and structural biology, vaccine development, and antiviral drug discovery for emerging RNA viruses that are current threats in Africa and included flaviviruses (dengue and Zika), alphaviruses (chikungunya), coronaviruses, filoviruses (Ebola), influenza viruses, Crimean Congo hemorrhagic fever virus, Rift Valley fever Virus, Lassa virus, and others. Data were presented on recent flavivirus and/or chikungunyavirus outbreaks in Angola, Burkina Faso, and Mozambique. In addition, these viruses are endemic in many sub-Saharan countries. The TASW series on emerging viruses is unique in Africa and successful in promoting collaborations between researchers in Africa and other parts of the world, as well as among African scientists. This report summarizes the lectures held at the meeting and highlights advances in the field. The 3rd Tofo Advanced Study Week on Emerging and Re-emerging Viruses took place from September 2–6, 2018. African attendees came from Angola, Botswana, Burkina Faso, the CAR, Mozambique, Nigeria, S Africa, Tanzania and Zimbabwe. Other participants were from Europe, China, Singapore, and the USA. This unique meeting enabled scientists from Africa and elsewhere to discuss problems and initiate new collaborations. Presentations covered dengue virus, Zika, chikungunya, coronaviruses, Ebola, influenza, Rift Valley fever, CCHF, and RSV.
Collapse
Affiliation(s)
- Athanase Badolo
- Laboratory of Fundamental and Applied Entomology, University Ouaga, Ouagadougou, Burkina Faso.
| | - Felicity Burt
- Division of Virology, National Health Laboratory Services and Faculty of Health Sciences, University of the Free State, Bloemfontein, South Africa.
| | - Susan Daniel
- Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY, USA.
| | - Rachel Fearns
- Boston University School of Medicine, Boston, MA, USA.
| | | | - Margaret Kielian
- Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY, USA.
| | - Julien Lescar
- Structural Biology and Biochemistry, Nanyang Technological University, Singapore.
| | - Yi Shi
- Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
| | - Albrecht von Brunn
- Max von Pettenkofer-Institute, Ludwig-Maximilians-University of Munich, Munich, Germany; German Center for Infection Research (DZIF), Munich Site, Munich, Germany.
| | - Susan R Weiss
- Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
| | - Rolf Hilgenfeld
- Institute of Biochemistry, University of Lübeck, Lübeck, Germany; German Center for Infection Research (DZIF), Hamburg - Lübeck - Borstel - Riems Site, Lübeck, Germany.
| |
Collapse
|
8
|
Simkins J, Anjan S, Morillas-Rodriguez JA, Greissman SR, Abbo LM, Camargo JF, Ruiz P, Vianna R, Guerra G, Salama S, Morris MI. Screening for Zika virus in deceased organ donors in Florida. Am J Transplant 2018; 18:731-736. [PMID: 29116671 DOI: 10.1111/ajt.14582] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2017] [Revised: 10/19/2017] [Accepted: 10/22/2017] [Indexed: 01/25/2023]
Abstract
Zika virus (ZIKV) cases have been detected across the United States (US) and locally acquired cases have been reported in Florida. Currently, there are no ZIKV screening guidelines and no data on the incidence among organ donors in the US. This retrospective study was conducted at Jackson Memorial-Miami Transplant Institute. Positive ZIKV tests in local deceased organ donors were investigated from 6/2016 to 1/2017. We evaluated demographics and risk factors for ZIKV infection among organ donors and transplant outcomes among recipients of donors with positive ZIKV testing. One hundred forty-two donors were analyzed. Ten percent had traveled to ZIKV-endemic countries and 19% had outdoor occupations. Only 3% had positive ZIKV IGG. None had a positive ZIKV IGM or PCR. ZIKV-positive donors were more likely to have traveled to ZIKV-endemic countries (50% vs. 9%, P = .05). The kidneys from a ZIKV-positive donor were transplanted in our hospital with no 6-month rejection, graft failure, or death in the recipients. Our study demonstrated a low prevalence of ZIKV among deceased donors in our community. Despite local ZIKV transmission, ZIKV was more common in donors who traveled to ZIKV-endemic countries. This cohort demonstrated excellent outcomes in recipients of ZIKV IGG-positive donors. However, larger studies are needed.
Collapse
Affiliation(s)
- J Simkins
- Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
| | - S Anjan
- Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
| | | | - S R Greissman
- University of Miami Miller School of Medicine, Miami, FL, USA
| | - L M Abbo
- Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
| | - J F Camargo
- Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
| | - P Ruiz
- Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, USA
| | - R Vianna
- Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, USA
| | - G Guerra
- Division of Nephrology, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
| | - S Salama
- Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, USA
| | - M I Morris
- Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
| |
Collapse
|